India’s health ministry has proposed medicine quality rules that would require regulators to suspend a manufacturing licence at once when a medicine fails specified quality standards in government testing. The draft, dated 28 October and published on Wednesday 4 November, covers failures for impurities, sterility, assay, which is the amount of active ingredient in a drug, and dissolution, which is how a drug releases its ingredient. Under the proposal, the licence would stay suspended until the manufacturer carries out effective root-cause analysis and corrective and preventive action to the satisfaction of the regulator.
The change in the proposed medicine quality rules targets a lag in the current system. At present, a drug declared “not of standard quality” (NSQ) goes through due process before action follows, and that process takes time. The proposed medicine quality rules would remove that delay for the specified failures, so suspension would follow the test result without waiting for the longer process to run its course. Regulators regularly identify batches that do not meet standards, and the ministry has framed the draft as a way to act faster when a batch fails.
What the medicine quality rules would change
The draft lists four kinds of failure that would trigger immediate suspension: impurities, sterility, assay and dissolution. Each test checks a different part of a medicine’s quality. Impurity tests look for unwanted substances. Sterility tests check whether a product meant to be sterile carries microbial contamination. Assay tests measure whether the amount of active ingredient matches the stated strength. Dissolution tests check whether the drug releases its ingredient in the way it should. A failure in any of these areas under the proposed medicine quality rules would lead to suspension of the manufacturing licence under the proposal.
Reinstatement would not be automatic. The manufacturer would need to identify the root cause of the failure, take corrective action to fix it, and take preventive action to stop it happening again. The regulator would need to be satisfied with that work before the licence could return. That condition puts the burden on the manufacturer to show, with evidence, that the problem has been understood and addressed, rather than simply waiting out a fixed period.
Why the medicine quality rules are being proposed now
The proposal comes amid closer scrutiny of drug manufacturing in India. Locally made cough syrups have been linked to child deaths in India, Gambia and Uzbekistan, and those cases have drawn attention to how quickly regulators act when a product fails a test. The draft does not name any company or product, but it sets out a general rule that would apply when government testing finds one of the specified failures.
Reuters reported last week that the regulator ordered Sun Pharmaceutical to stop making, selling and distributing ophthalmic products at its Assam facility after quality management failures. That order was separate from the new draft, but it shows the kind of enforcement action regulators have taken in recent weeks. The Central Drugs Standard Control Organisation (CDSCO) also publishes monthly NSQ alerts, which list batches found not to meet standards.
Consultation and next steps for the medicine quality rules
The draft medicine quality rules are open for comments within 30 days. After that period, the ministry will consider the responses before deciding on a final version. The proposal would take effect on final publication in the Gazette, the official record in which such rules are published. Until then, the existing process remains in place.
For manufacturers, the medicine quality rules signal a stricter timetable. A failed test for one of the listed parameters would mean an immediate halt to production under that licence, and a return to production would depend on work the regulator accepts. For patients and doctors, the practical effect would be faster removal of a failing product’s maker from production while the fault is investigated.
The ministry has not stated a date for the final rules beyond the Gazette publication step. Companies, doctors, patient groups and other interested parties have the 30 day window to send comments on the draft. The final text may change in response to those comments, and the ministry will publish the outcome when the process is complete.